Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcome...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1141500/full |
_version_ | 1797845574871941120 |
---|---|
author | Lorena Incorvaia Alessandra Dimino Laura Algeri Chiara Brando Luigi Magrin Ida De Luca Erika Pedone Alessandro Perez Roberta Sciacchitano Annalisa Bonasera Tancredi Didier Bazan Russo Federica Li Pomi Marta Peri Valerio Gristina Antonio Galvano Dario Giuffrida Ivan Fazio Francesca Toia Adriana Cordova Ada Maria Florena Antonio Giordano Viviana Bazan Viviana Bazan Antonio Russo Antonio Russo Giuseppe Badalamenti |
author_facet | Lorena Incorvaia Alessandra Dimino Laura Algeri Chiara Brando Luigi Magrin Ida De Luca Erika Pedone Alessandro Perez Roberta Sciacchitano Annalisa Bonasera Tancredi Didier Bazan Russo Federica Li Pomi Marta Peri Valerio Gristina Antonio Galvano Dario Giuffrida Ivan Fazio Francesca Toia Adriana Cordova Ada Maria Florena Antonio Giordano Viviana Bazan Viviana Bazan Antonio Russo Antonio Russo Giuseppe Badalamenti |
author_sort | Lorena Incorvaia |
collection | DOAJ |
description | BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with avelumab as first-line treatment. The study population included the patients treated from February 2019 to October 2022 in an Italian referral center for rare tumors. Clinico-pathological characteristics, BMI, laboratory parameters (NLR and platelet count), and response to avelumab were analyzed from a MCC System database prospectively collected.ResultsThirty-two (32) patients were included. Notably, the presence of pre-treatment BMI ≥ 30 was significantly associated with longer PFS [BMI < 30 Group: median PFS, 4 months (95% CI: 2.5-5.4); BMI ≥ 30 Group: median PFS, not reached; p<0.001)[. Additionally, the median PFS was significantly higher in patients with higher PLT (median PFS: 10 months in the “low PLT” Group (95% CI: 4.9, 16.1) vs 33 months (95% CI: 24.3, 43.2) in the “high PLT” Group (p=0.006). The multivariable Cox regression model confirmed these results.ConclusionTo our knowledge, this is the first study that investigates the predictive role of BMI in MCC patients. Our data were consistent with the clinical observation of improved outcomes in obese patients across other tumor types. Thus, advanced age, a weakened immune system, and the obesity-associated “inflammaging”, are key factors that could impact the cancer immune responses of mMCC patients. |
first_indexed | 2024-04-09T17:41:14Z |
format | Article |
id | doaj.art-f2080b4c58df4c2da93ca0c2857999d3 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-04-09T17:41:14Z |
publishDate | 2023-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-f2080b4c58df4c2da93ca0c2857999d32023-04-17T05:44:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11415001141500Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumabLorena Incorvaia0Alessandra Dimino1Laura Algeri2Chiara Brando3Luigi Magrin4Ida De Luca5Erika Pedone6Alessandro Perez7Roberta Sciacchitano8Annalisa Bonasera9Tancredi Didier Bazan Russo10Federica Li Pomi11Marta Peri12Valerio Gristina13Antonio Galvano14Dario Giuffrida15Ivan Fazio16Francesca Toia17Adriana Cordova18Ada Maria Florena19Antonio Giordano20Viviana Bazan21Viviana Bazan22Antonio Russo23Antonio Russo24Giuseppe Badalamenti25Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Oncology, Istituto Oncologico del Mediterraneo, Catania, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyDepartment of Oncology, Istituto Oncologico del Mediterraneo, Catania, ItalyRadiotherapy Unit, Clinica Macchiarella, Palermo, ItalyDivision of Plastic and Reconstructive Surgery, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, ItalyDivision of Plastic and Reconstructive Surgery, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, ItalyPathologic Anatomy Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, ItalySbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United StatesDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (Bind.), Section of Medical Oncology, University of Palermo, Palermo, ItalyInstitute for Cancer Research and Molecular Medicine and Center of Biotechnology, Temple University, Philadelphia, PA, United StatesDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyInstitute for Cancer Research and Molecular Medicine and Center of Biotechnology, Temple University, Philadelphia, PA, United StatesDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyBackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with avelumab as first-line treatment. The study population included the patients treated from February 2019 to October 2022 in an Italian referral center for rare tumors. Clinico-pathological characteristics, BMI, laboratory parameters (NLR and platelet count), and response to avelumab were analyzed from a MCC System database prospectively collected.ResultsThirty-two (32) patients were included. Notably, the presence of pre-treatment BMI ≥ 30 was significantly associated with longer PFS [BMI < 30 Group: median PFS, 4 months (95% CI: 2.5-5.4); BMI ≥ 30 Group: median PFS, not reached; p<0.001)[. Additionally, the median PFS was significantly higher in patients with higher PLT (median PFS: 10 months in the “low PLT” Group (95% CI: 4.9, 16.1) vs 33 months (95% CI: 24.3, 43.2) in the “high PLT” Group (p=0.006). The multivariable Cox regression model confirmed these results.ConclusionTo our knowledge, this is the first study that investigates the predictive role of BMI in MCC patients. Our data were consistent with the clinical observation of improved outcomes in obese patients across other tumor types. Thus, advanced age, a weakened immune system, and the obesity-associated “inflammaging”, are key factors that could impact the cancer immune responses of mMCC patients.https://www.frontiersin.org/articles/10.3389/fonc.2023.1141500/fullMerkel cell carcinoma (MCC)avelumabbody mass index - BMIpredictive factorsimmunotherapyskin cancer non melanoma |
spellingShingle | Lorena Incorvaia Alessandra Dimino Laura Algeri Chiara Brando Luigi Magrin Ida De Luca Erika Pedone Alessandro Perez Roberta Sciacchitano Annalisa Bonasera Tancredi Didier Bazan Russo Federica Li Pomi Marta Peri Valerio Gristina Antonio Galvano Dario Giuffrida Ivan Fazio Francesca Toia Adriana Cordova Ada Maria Florena Antonio Giordano Viviana Bazan Viviana Bazan Antonio Russo Antonio Russo Giuseppe Badalamenti Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab Frontiers in Oncology Merkel cell carcinoma (MCC) avelumab body mass index - BMI predictive factors immunotherapy skin cancer non melanoma |
title | Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
title_full | Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
title_fullStr | Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
title_full_unstemmed | Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
title_short | Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
title_sort | body mass index and baseline platelet count as predictive factors in merkel cell carcinoma patients treated with avelumab |
topic | Merkel cell carcinoma (MCC) avelumab body mass index - BMI predictive factors immunotherapy skin cancer non melanoma |
url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1141500/full |
work_keys_str_mv | AT lorenaincorvaia bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT alessandradimino bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT lauraalgeri bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT chiarabrando bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT luigimagrin bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT idadeluca bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT erikapedone bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT alessandroperez bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT robertasciacchitano bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT annalisabonasera bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT tancredididierbazanrusso bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT federicalipomi bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT martaperi bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT valeriogristina bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT antoniogalvano bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT dariogiuffrida bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT ivanfazio bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT francescatoia bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT adrianacordova bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT adamariaflorena bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT antoniogiordano bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT vivianabazan bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT vivianabazan bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT antoniorusso bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT antoniorusso bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab AT giuseppebadalamenti bodymassindexandbaselineplateletcountaspredictivefactorsinmerkelcellcarcinomapatientstreatedwithavelumab |